Interstitial lung disease — diagnostic approach (MDT)
DPLD work-up · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Diffuse parenchymal lung disease encompasses hundreds of entities; accurate classification drives prognosis and treatment. A multidisciplinary approach integrating clinical, radiological and (where needed) pathological data is the diagnostic gold standard.
Red flags
- Rapid progression / acute exacerbation
- Resting hypoxaemia at presentation
- Features of connective-tissue disease or vasculitis
- Honeycombing with declining FVC
Assessment
Differential diagnosis
- Idiopathic pulmonary fibrosis (UIP)
- Connective-tissue-disease ILD
- Hypersensitivity pneumonitis
- Sarcoidosis
- Drug-induced ILD
- Occupational/pneumoconiosis
- Organising pneumonia
Investigations
- Detailed history: exposures, drugs, occupation, connective-tissue symptoms, family history
- HRCT chest with inspiratory/expiratory and prone sequences
- Full lung function: spirometry, lung volumes, DLCO, walk test with oximetry
- Autoimmune panel (ANA, ENA, RF, anti-CCP, myositis panel, ANCA)
- Precipitins / specific IgG for HP antigens
- BAL and/or lung cryobiopsy/surgical biopsy when diagnosis remains uncertain
- Echocardiogram for pulmonary hypertension screen
Management
- Take a comprehensive exposure, drug, occupational and autoimmune history
- Examine for clubbing, crackles, extrapulmonary (skin, joint, muscle) signs
- Obtain a high-quality HRCT and define the pattern (UIP, NSIP, OP, HP)
- Characterise physiology with full lung function and desaturation on exertion
- Send a targeted serological panel to detect occult connective-tissue disease
- Reserve BAL and biopsy for cases where imaging/clinical data are insufficient
- Bring all data to an ILD multidisciplinary meeting for consensus diagnosis
- Assign a working diagnosis and define the progressive-fibrosing risk
- Decide therapy: immunosuppression for inflammatory, antifibrotics for progressive fibrosis
- Set up longitudinal monitoring, supportive care and transplant consideration
Drugs & doses
No empirical therapy before MDT diagnosis; treatment is diagnosis-specific
Oxygen as needed for exertional/resting hypoxaemia
Vaccination (influenza, pneumococcal, COVID-19) as supportive care
Disposition
ILD specialist centre with MDT; early transplant referral for progressive disease.
Complications & pitfalls
- Misclassification leading to wrong treatment
- Progression to respiratory failure
- Pulmonary hypertension
- Biopsy-related acute exacerbation
Exam pearls
- A confident multidisciplinary diagnosis outperforms any single test
- Myositis-specific antibodies (e.g. anti-MDA5, anti-Jo1) explain many 'idiopathic' ILDs
- Prone HRCT distinguishes dependent atelectasis from true early fibrosis
- Treat the progressive fibrosing phenotype even when the underlying label is uncertain
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.